A comparative study of European rare disease and orphan drug markets-Reference-Cited by-同舟云学术

A comparative study of European rare disease and orphan drug markets

Published:2010-10 Issue:2-3 Volume:97 Page:173-179
ISSN:0168-8510
Container-title:Health Policy
language:en
Short-container-title:Health Policy

Author:

Denis Alain,Mergaert Lut,Fostier Christel,Cleemput Irina,Simoens Steven

Publisher

Elsevier BV

Subject

Health Policy

Reference19 articles.

1. European Commission. European Commission Regulation (EC) No 141/2000 of the European Parliament and the Council of 16 December 1999 on orphan medicinal products;Official Journal of the European Communities,2000

2. Annual report of the European Medicines Agency 2007;European Medicines Agency,2008

3. Health technology assessment policy governing rare diseases and orphan medicines;Denis,2009

4. Les maladies orphelines et les médicaments orphelins: une analyse Belge et Européenne;Denis;Journal de Pharmacie de Belgique,2009

5. Health at a glance 2007;Organisation for Economic Co-operation and Development,2007

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Framework for Multistakeholder Patient Registries in the Field of Rare Diseases;Neurology;2024-09-24

2. Landscape analysis of available European data sources amenable for machine learning and recommendations on usability for rare diseases screening;Orphanet Journal of Rare Diseases;2024-04-06

3. Challenges in mapping European rare disease databases, relevant for ML-based screening technologies in terms of organizational, FAIR and legal principles: scoping review;Frontiers in Public Health;2023-09-15

4. Determinants of dental care use in patients with rare diseases: a qualitative exploration;BMC Oral Health;2023-06-22

5. Making orphan drugs and services available and accessible for people who live with rare diseases: what has been done? a systematic scoping review;Expert Opinion on Orphan Drugs;2022-12-02